The dark side of mast cell-targeted therapy in prostate cancer

Cancer Research

Volumn 72, Issue 4, 2012, Pages 831-835

  Pittoni, Paola ^a   Colombo, Mario Paolo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CROMOGLYCATE DISODIUM; GELATINASE B; IMATINIB; MATRIX METALLOPROTEINASE INHIBITOR; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR;

ANTINEOPLASTIC ACTIVITY; BYSTANDER EFFECT; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; CELL CLONE; CELL FUNCTION; CELL INFILTRATION; CELL INTERACTION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); ENZYME SYNTHESIS; EPITHELIAL MESENCHYMAL TRANSITION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MALIGNANT TRANSFORMATION; MAST CELL; MOLECULARLY TARGETED THERAPY; NEUROSECRETORY CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTECTION; PROTEIN EXPRESSION; REVIEW; TUMOR MICROENVIRONMENT;

ANIMALS; HUMANS; MALE; MAST CELLS; MOLECULAR TARGETED THERAPY; NEUROENDOCRINE TUMORS; OXIDOREDUCTASES; PROSTATIC NEOPLASMS;

EID: 84857201114     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3110     Document Type: Review

References (33)

1. Coussens LM, Werb Z. Inflammatory cells and cancer: think different! J Exp Med 2001;193:F23-6. (Pubitemid 32524459)
2. Crivellato E, Beltrami C, Mallardi F, Ribatti D. Paul Ehrlich's doctoral thesis: a milestone in the study of mast cells. Br J Haematol 2003;123:19-21.
3. Wasiuk A, de Vries VC, Hartmann K, Roers A, Noelle RJ. Mast cells as regulators of adaptive immunity to tumours. Clin Exp Immunol 2009;155:140-6.
4. Theoharides TC, Conti P. Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol 2004;25:235-41. (Pubitemid 38501669)
5. Maltby S, Khazaie K, McNagny KM. Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta 2009;1796:19-26.
6. Galinsky DS, Nechushtan H. Mast cells and cancer - no longer just basic science. Crit Rev Oncol Hematol 2008;68:115-30.
7. Khazaie K, Blatner NR, Khan MW, Gounari F, Gounaris E, Dennis K, et al. The significant role of mast cells in cancer. Cancer Metastasis Rev 2011;30:45-60.
8. Johansson A, Rudolfsson S, Hammarsten P, Halin S, Pietras K, Jones J, et al. Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am J Pathol 2010;177:1031-41.
9. Sari A, Serel TA, Candir O, Oztürk A, Kosar A. Mast cell variations in tumour tissue and with histopathological grading in specimens of prostatic adenocarcinoma. BJU Int 1999;84:851-3. (Pubitemid 29500055)
10. Fleischmann A, Schlomm T, Köllermann J, Sekulic N, Huland H, Mirlacher M, et al. Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis. Prostate 2009;69:976-81.
11. Pittoni P, Tripodo C, Piconese S, Mauri G, Parenza M, Rigoni A, et al. Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. Cancer Res 2011;71:5987-97.
12. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995;92:3439-43.
13. Tang Y, Wang L, Goloubeva O, Khan MA, Lee D, Hussain A. The relationship of neuroendocrine carcinomas to anti-tumor therapies in TRAMP mice. Prostate 2009;69:1763-73.
14. Huang B, Lei Z, Zhang GM, Li D, Song C, Li B, et al. SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood 2008;112:1269-79.
15. Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000;103:481-90.
16. Kanbe N, Tanaka A, Kanbe M, Itakura A, Kurosawa M, Matsuda H. Human mast cells produce matrix metalloproteinase 9. Eur J Immunol 1999;29:2645-9. (Pubitemid 29378135)
17. Chiaverotti T, Couto SS, Donjacour A, Mao JH, Nagase H, Cardiff RD, et al. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol 2008;172:236-46. (Pubitemid 351186384)
18. Leong KG, Wang BE, Johnson L, Gao WQ. Generation of a prostate from a single adult stem cell. Nature 2008;456:804-8.
19. Miyamoto H, Altuwaijri S, Cai Y, Messing EM, Chang C. Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer. Mol Carcinog 2005;44:1-10. (Pubitemid 41216402)
20. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-92. (Pubitemid 34270240)
21. Piconese S, Costanza M, Musio S, Tripodo C, Poliani PL, Gri G, et al. Exacerbated experimental autoimmune encephalomyelitis in mast-cell-deficient Kit(W-sh/W-sh) mice. Lab Invest 2011;91:627-41.
22. Zitvogel L, Kroemer G. Anticancer effects of imatinib via immunostimulation. Nat Med 2011;17:1050-1.
23. Bajaj GK, Zhang Z, Garrett-Mayer E, Drew R, Sinibaldi V, Pili R, et al. Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy. Urology 2007;69:526-31. (Pubitemid 46428397)
24. Rao K, Goodin S, Levitt MJ, Dave N, Shih WJ, Lin Y, et al. A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate 2005;62:115-22. (Pubitemid 40096777)
25. Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, et al. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int 2006;98:763-9. (Pubitemid 44368021)
26. Tiffany NM, Wersinger EM, Garzotto M, Beer TM. Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer. Urology 2004;63:934-9. (Pubitemid 38596682)
27. Mathew P, Thall PF, Jones D, Perez C, Bucana C, Troncoso P, et al. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol 2004;22:3323-9. (Pubitemid 41103689)
28. Huss WJ, Gray DR, Tavakoli K, Marmillion ME, Durham LE, Johnson MA, et al. Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model. Neoplasia 2007;9:938-50. (Pubitemid 350086439)
29. Ippolito JE, Xu J, Jain S, Moulder K, Mennerick S, Crowley JR, et al. An integrated functional genomics and metabolomics approach for defining poor prognosis in human neuroendocrine cancers. Proc Natl Acad Sci U S A 2005;102:9901-6. (Pubitemid 40993665)
30. Taylor AM, Galli SJ, Coleman JW. Stem-cell factor, the kit ligand, induces direct degranulation of rat peritoneal mast cells in vitro and in vivo: dependence of the in vitro effect on period of culture and comparisons of stem-cell factor with other mast cell-activating agents. Immunology 1995;86:427-33.
31. Babina M, Rex C, Guhl S, Thienemann F, Artuc M, Henz BM, et al. Baseline and stimulated turnover of cell surface c-Kit expression in different types of human mast cells. Exp Dermatol 2006;15:530-7. (Pubitemid 43834488)
32. Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J, et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 2011;121:1298-312.
33. Wiesner C, Nabha SM, Dos Santos EB, Yamamoto H, Meng H, Melchior SW, et al. C-kit and its ligand stem cell factor: potential contribution to prostate cancer bone metastasis. Neoplasia 2008;10:996-1003.